Phase 3Terminated
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma (PICASSO III)
A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.
- Sponsor
- Alaunos Therapeutics (Industry)
- Enrolment
- 447 enrolled
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Palifosfamide-Tris; doxorubicin; Placebo
- Ages
- adults, older adults
- Registry
- NCT01168791
From the registry
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).
Primary outcomes
- Progression Free Survival followed by Overall Survival